Internistisch-onkologische Therapiestrategien bei kolorektalen Karzinomen

  • F. Overkamp
  • J. Orzessek
Conference paper

Zusammenfassung

Der Begriff „Therapiestrategien“ könnte übertriebene Erwartungen wecken und fälschlicherweise signalisieren, es stünden bewährte, durchgreifende, sicheren Erfolg versprechende internistisch-onkologische Behandlungsmöglichkeiten zur Verfügung. Hämatoonkologen neigen zumindest gelegentlich zu dem Versuch, einen Mangel an bahnbrechenden Behandlungsvorschlägen durch besonders hochtrabende Formulierungen zu kompensieren. Es gibt zwar eine Reihe von Fortschritten sowie interessante, partiell erfolgreiche und hoffnungsvolle Therapieansätze, aber Tatsache bleibt zum gegenwärtigen Zeitpunkt, daß trotz neuer Anstrengungen zur Prävention, trotz Früherkennungsmaßnahmen und weiterentwickelter Therapiemodalitäten die Fünfjahresüberlebensraten bei kolorektalen Karzinomen nahezu unverändert geblieben sind [19, 24].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ajani JA, Rios AA, Ende K et al. (1989) Phase I und II studies of the combination of recombinant human interferon-gamma und 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod 8: 140PubMedGoogle Scholar
  2. 2.
    Buyse M (1988) Adjuvant therapy of colorectal cancer. JAMA 259: 3571PubMedCrossRefGoogle Scholar
  3. 3.
    Bägli DJ, Steele GD, Barlozzari T (1989) Natural killer sensitivity of colorectal carcinoma targets. Correlation with degree of differentiation. Arch Surg 124: 89Google Scholar
  4. 4.
    Carter SK, Friedmann M (1974) Integration of chemotherapy into combined-modality treatment of solid tumours. Cancer Treat Rev 1: 111CrossRefGoogle Scholar
  5. 5.
    Der Arzneimittelbrief (1991) Nr. 9Google Scholar
  6. 6.
    DeVita VT, Hellmann S, Rosenberg St (1991) The efficacy and the group C status of levamisole and 5-fluorouracil for patients with Dukes C colon cancer. Lippincott, Philadelphia, Appendix B, 251 (Important advances in oncology)Google Scholar
  7. 7.
    Einhorn LH (1989) Improvements in fluorouracil chemotherapy? J Clin Oncol 7: 1377PubMedGoogle Scholar
  8. 8.
    Erlichman C, Fine S, Wong A, Elhakim T (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469PubMedGoogle Scholar
  9. 9.
    Fryta KS, Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ (1975) Adriamycin (NSC-123127) therapy for advanced gastrointestinal cancer. Cancer Chemother Rep 59: 405Google Scholar
  10. 10.
    Gawenda M, Prokop A, Huber R, Pichlmaier H (1991) Lokale Chemotherapie der Leber bei nicht resektablen Lebermetastasen kolorektaler Karzinome. Tumordiagn Ther 12: 186–191Google Scholar
  11. 11.
    Hines J, Adelstein D, Bast J, Spiess J (1988) High dose oral leucovorin and intravenous 5-fluorouracil in advanced metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 7: 110Google Scholar
  12. 12.
    Hines J, Zaken M, Adelstein D, Rustum Y (1988) Treatment of advanced-stage colorectal adenocarcinoma with fluorouracil and high dose leucovorin calcium: a pilot study. J Clin Oncol 6: 142PubMedGoogle Scholar
  13. 13.
    Hryniuk WM, Figueredo A, Goodyear M (1987) Applications on dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14: 3PubMedGoogle Scholar
  14. 14.
    Huberman M, Bering H, Tessitore J, Groopman J, Tran L, Young D, Evans L (1990) 5-fluorouracil (5-FU) plus recombinant alpha interferon (Roferon A) in advanced colorectal cancer. Proc ASCO 9: 116Google Scholar
  15. 15.
    Kelm C, Schwemmle K, Henneking K, Quoika P (1992) Behandlungsmöglichkeiten maligner Lebertumoren. Klinikarzt 21, 1:23 ff.Google Scholar
  16. 16.
    Kemeny N, Daly J, Oderuran P, Shike M, Chun H, Petroni G, Geller (1984) Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 2: 595Google Scholar
  17. 17.
    Kemeny N, Kelsen D, Derby S, Sammarco P, Adams L, Murray P (1990) Combination of 5-fluorouracil (FU) and recombinant alpha-interferon (Ifn) in advanced colorectal carcinoma: activity but significant toxicity. Proc ASCO 9: 109Google Scholar
  18. 18.
    Klein ISO, Golbach G, Voigt P, Coerper C, Bernhard C (1990) Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer. 15`h International Cancer Congress, Hamburg, August 16Google Scholar
  19. 19.
    Klein HO (1991) Chemo-und Immunotherapie des kolorektalen Karzinoms. Internist 32: 348–353PubMedGoogle Scholar
  20. 20.
    Krown SE, Mintzer D, Cunningham-Rundles S. Niedzwieki D, Krim M, Einzig Al, Gabrilove JL, Shurgot B, Gessula J (1987) High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses. Cancer Treat Rep 71: 39PubMedGoogle Scholar
  21. 21.
    Lillis PK, Brown TD, Beougher K, Koeller J, Marcus SG, von Hoff DD (1987) Phase II trial of recombinant beta interferon in advanced colorectal cancer. Cancer Treat Rep 71: 965PubMedGoogle Scholar
  22. 22.
    Lokich J, Ahlgren J, Gullo J, Phillips J, Freyer J (1987) A randomized trial of standard bolus 5-FU vs protracted infusional 5-FU in advanced colorectal cancer. Proc Am Soc Clin Oncol 6: 81Google Scholar
  23. 23.
    Moertel CG (1969) Natural History of Gastrointestinal Cancer. In: Moertel CG, Reitemeier RJ (eds) Advanced gastrointestinal cancer. Clinical management and chemotherapy. Harper Row, New York, p 3Google Scholar
  24. 24.
    Moertel CG (1975) Clinical management of advanced gastrointestinal cancer. Cancer 36: 675PubMedCrossRefGoogle Scholar
  25. 25.
    Moertel CG, Fleming TR, MacDonald JS et al. (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352PubMedCrossRefGoogle Scholar
  26. 26.
    Muggia FM, Groshen S (1991) Adjuvant therapy of colon cancer: Lessons while looking for breakthroughs. Ann Oncol 2: 641–644Google Scholar
  27. 27.
    Niederhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E (1984) Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 53: 1336PubMedCrossRefGoogle Scholar
  28. 28.
    Niederle N, Kurschel E, Schmidt CG (1984) Biologischer Effekt von rekombiniertem Leukozyten-alpha2-Interferon bei metastasierten kolorektalen Karzinomen. Dtsch Med Wochenschr 109: 779PubMedCrossRefGoogle Scholar
  29. 29.
    Nobile M, Vidili M, Sobrero A, Sertoli M, Canobbio L, Fassio T, Rubagotti A, Gallo L, Lore G, Galligioni E, Rosso R (1988) 5-fluorouracil in advanced metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 7: 97Google Scholar
  30. 30.
    O’Connell M, Poon M, Wieand H, Moertel C, Krook J, Gerstner J (1990) Biochemical modulation of 5-fluorouracil (5-FU) with leucovorin (LV): confirmatory evidence of improved therapeutic efficacy in the treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 9: 106Google Scholar
  31. 31.
    Overkamp F (1992) Internistisch-onkologische Therapiestrategien bei kolorektalen Karzinomen. (Vortrag im Rahmen der 18. Coloproktologie-Tage Bad Homburg 7. 3. 1992 )Google Scholar
  32. 32.
    Pazdur R, Abbruzzese J, Faintuch J et al. (1990) Phase II study of recombinant interferon alpha (rIFN) and 5-fluorouracil (5-FU) in patients (PTS) with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 9: 117Google Scholar
  33. 33.
    Pestana C, Reitemeier RJ, Moertel CG, Judd ES, Dougherty (1974) The natural history of carcinoma of the colon and rectum. Am J Surg 108: 826Google Scholar
  34. 34.
    Petrelli N, Stablein D, Bruckner H, Meqibow A, Meyer R, Douglas H (1988) Prospective randomized phase III trial of 5-fluorouracil (5-FU) vs 5-FU and high dose leucovorin (HDCF) vs 5-FU and low dose leucovorin (LDCF) in patients with metastatic colorectal adeno-carcinoma. A report of the Gastro-Intestinal Tumor Study Group. Proc Am Soc Clin Oncol 7: 94Google Scholar
  35. 35.
    Prokop A, Tilbergen D, Pichlmaier H (1991) Chirurgische Therapie des kolorektalen Karzinoms. Internist 32: 335–347PubMedGoogle Scholar
  36. 36.
    Rosenberg SA (1988) Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 9: 58PubMedCrossRefGoogle Scholar
  37. 37.
    Sauer R (1989) Praeoperative Strahlentherapie beim Rektumkarzinom. Onkologie 12 (Suppl 2): 1–33CrossRefGoogle Scholar
  38. 38.
    Scheithauer W (1989) Palliative Chemotherapie und Immuntherapie des kolorektalen Karzinoms. Tumordiagn Ther 10: 1Google Scholar
  39. 39.
    Triozzi PL, Kenney P, Young D, Rinehart JJ (1987) Open-label phase II trial of recombinant beta interferon (IFN-beta) in patients with colorectal cancer. Cancer Treat Rep 71: 983PubMedGoogle Scholar
  40. 40.
    Ultman P, Philips H (1982) Survival response to chemotherapy for advanced colorectal adenocarcinoma. Cancer 49: 1536Google Scholar
  41. 41.
    Valone F, Drakes T, Flam M, Hannigan J (1988) Randomized trial of 5-FU vs. leucovorin plus 5-FU vs. sequential methotrexate, 5-FU leucovorin in patients with advanced colorectal carcinom. Proc Am Soc Clin Oncol 7: 95Google Scholar
  42. 42.
    Wade J, Herbst S (1988) Prolonged venous infusion (PVI) of 5-fluorouracil for metastatic colon cancer: a follow-up report. Am Soc Clin Oncol 7: 94Google Scholar
  43. 43.
    Wadler S, Schwartz EL, Goldman M et al. (1989) Fluorouracil and recombinant alfa2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769PubMedGoogle Scholar
  44. 44.
    Watkins E, Khazei A, Nahra KS (1970) Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver. Surg Gynecol Obstet 130: 580Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • F. Overkamp
  • J. Orzessek

There are no affiliations available

Personalised recommendations